Gilgamesh Pharma Files Form D for Exempt Securities Offering

TL;DR

**Gilgamesh Pharma just filed a D, they're raising capital privately.**

AI Summary

Gilgamesh Pharma Inc. filed a Form D on March 24, 2026, indicating a notice of an exempt offering of securities. This filing, with SEC Accession No. 0002107396-26-000003, suggests the company is raising capital outside of a public registration, likely from accredited investors. For current or potential shareholders, this means the company is securing funding, which could be used for operations, research, or expansion, potentially diluting existing shares if new equity is issued, but also fueling growth.

Why It Matters

This filing signals Gilgamesh Pharma is raising capital, which can fund growth but might also lead to share dilution for existing investors.

Risk Assessment

Risk Level: medium — While raising capital can be positive, the details of the offering (e.g., equity vs. debt, valuation) are not disclosed in a Form D, introducing uncertainty about potential dilution or debt burden.

Analyst Insight

Investors should monitor for subsequent announcements or filings that might reveal the terms of this exempt offering, such as the amount raised, type of securities, and potential impact on existing share structure.

Key Players & Entities

• Gilgamesh Pharma Inc. (company) — the filer of the Form D
• 0002107396 (company) — CIK of Gilgamesh Pharma Inc.
• 2026-03-24 (date) — filing and effectiveness date of the Form D

FAQ

Key Financial Figures

• $1 — enues   No Aggregate Net Asset Value   $1 - $1,000,000 $1 - $5,000,000   $1,000,
• $1,000,000 — No Aggregate Net Asset Value   $1 - $1,000,000 $1 - $5,000,000   $1,000,001 - $5,000,
• $5,000,000 — Net Asset Value   $1 - $1,000,000 $1 - $5,000,000   $1,000,001 - $5,000,000   $5,000,001
• $1,000,001 — e   $1 - $1,000,000 $1 - $5,000,000   $1,000,001 - $5,000,000   $5,000,001 - $25,000,000
• $5,000,001 — $5,000,000   $1,000,001 - $5,000,000   $5,000,001 - $25,000,000 $5,000,001 - $25,000,000
• $25,000,000 — $1,000,001 - $5,000,000   $5,000,001 - $25,000,000 $5,000,001 - $25,000,000   $25,000,001
• $25,000,001 — $25,000,000 $5,000,001 - $25,000,000   $25,000,001 - $50,000,000 $25,000,001 - $100,000,0
• $50,000,000 — 5,000,001 - $25,000,000   $25,000,001 - $50,000,000 $25,000,001 - $100,000,000   $50,000,0
• $100,000,000 — 25,000,001 - $50,000,000 $25,000,001 - $100,000,000   $50,000,001 - $100,000,000   Over $1
• $50,000,001 — 0,000,000 $25,000,001 - $100,000,000   $50,000,001 - $100,000,000   Over $100,000,000   O

Filing Documents

• primary_doc.html (D)
• primary_doc.xml (D) — 9KB
• 0002107396-26-000003.txt ( ) — 10KB

From the Filing

Form D FORM D Notice of Exempt Offering of Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. OMB APPROVAL OMB Number: 3235-0076 Estimated Average burden hours per response: 4.0 1. Issuer's Identity CIK (Filer ID Number) Previous Name(s) None Entity Type Corporation Limited Partnership   Limited Liability Company   General Partnership   Business Trust Other   Name of Issuer   Gilgamesh Pharma Inc. Jurisdiction of Incorporation/Organization DELAWARE   Year of Incorporation/Organization Over Five Years Ago Within Last Five Years (Specify Year) 2025 Yet to Be Formed           2. Principal Place of Business and Contact Information Name of Issuer   Gilgamesh Pharma Inc. Street Address 1 Street Address 2   113 UNIVERSITY PLACE, SUITE 1019     NEW YORK   NEW YORK     10003   929-723-4861   3. Related Persons Last Name First Name Middle Name Sporn Jonathan Street Address 1 Street Address 2   113 University Place, Suite 1019       New York   NEW YORK   10003   Relationship: Executive Officer Director Promoter Clarification of Response (if Necessary)   Last Name First Name Middle Name Kruegel Andrew Street Address 1 Street Address 2   113 University Place, Suite 1019       New York   NEW YORK   10003   Relationship: Executive Officer Director Promoter Clarification of Response (if Necessary)   Last Name First Name Middle Name Huque Zia Street Address 1 Street Address 2   113 University Place, Suite 1019       New York   NEW YORK   10003   Relationship: Executive Officer Director Promoter Clarification of Response (if Necessary)   Last Name First Name Middle Name Kruse Amy Street Address 1 Street Address 2   113 University Place, Suite 1019       New York   NEW YORK   10003   Relationship: Executive Officer Director Promoter Clarification of Response (if Necessary)   Last Name First Name Middle Name Berman Robert Street Address 1 Street Address 2   113 University Place, Suite 1019       New York   NEW YORK   10003   Relationship: Executive Officer Director Promoter Clarification of Response (if Necessary)   Last Name First Name Middle Name Skolnick Phil Street Address 1 Street Address 2   113 University Place, Suite 1019       New York   NEW YORK   10003   Relationship: Executive Officer Director Promoter Clarification of Response (if Necessary)   4. Industry Group   Agriculture Banking & Financial Services     Commercial Banking     Insurance   Investing     Investment Banking     Pooled Investment Fund   Other Banking & Financial Services   Business Services Energy     Coal Mining     Electric Utilities     Energy Conservation     Environmental Services     Oil & Gas     Other Energy Health Care     Biotechnology     Health Insurance     Hospitals & Physicians     Pharmaceuticals     Other Health Care                         Manufacturing Real Estate   Commercial   Construction   REITS & Finance   Residential Other Real Estate   Retailing Restaurants Technology   Computers   Telecommunications   Other Technology Travel   Airlines & Airports   Lodging & Conventions   Tourism & Travel Services   Other Travel Other        5. Issuer Size Revenue Range Aggregate Net Asset Value Range No Revenues   No Aggregate Net Asset Value   $1 - $1,000,000 $1 - $5,000,000   $1,000,001 - $5,000,000   $5,000,001 - $25,000,000 $5,000,001 - $25,000,000   $25,000,001 - $50,000,000 $25,000,001 - $100,000,000   $50,000,001 - $100,000,000   Over $100,000,000   Over $100,000,000   Decline to Disclose   Decline to Disclose   Not Applicable   Not Applicable   6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply) Rule 504(b)(1) (not (i), (ii) or (iii)) Rule 506(b)         Rule 504 (b)(1)(i) Rule 506(c) Rule 504 (b)(1)(ii) Securities Act Section 4(a)(5) Rule 504 (b)(1)(iii) Investment Company Act Section 3(c)     7. Type of Filing   New Notice Date of First Sale   2026-03-09   First Sale Yet to Occur   Amendment     8. Duration of Offering Does the Issuer intend this offering to last more than one year?   Yes   No     9. Type(s) of Securities Offered (select all that apply) Pooled Investment Fund Interests Equity Tenant-in-Common Securities Debt Mineral Property Securities Option, Warrant or Other Right to Acquire Another Security Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security Other (describe) Shares of Preferred Stock of Issuer and the shares of capital stock of Issuer into which such shares of Preferred Stock may convert.     10. Business Combination Transaction Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer?   Yes   No Clarification of Response (if Necessary)       11. Minimum Investment Minimum investment accepted

View Full Filing

View this D filing on SEC EDGAR